Specific Detection and Enumeration of *Burkholderia cepacia* Complex by Flow Cytometry Using a Fluorescence-Labeled Oligonucleotide Probe

Soumana Daddy Gaoh 1,†, Anna Williams 2,†, David Le 1, Ohgew Kweon 1, Pierre Alusta 2, Dan A. Buzatu 2 and Youngbeom Ahn 1,*

1 Division of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; soumana.daddy-gaoh@fda.hhs.gov (S.D.G.); ledavi73@students.rowan.edu (D.L.); oh-gew.kweon@fda.hhs.gov (O.K.)
2 Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; anna.williams@fda.hhs.gov (A.W.); pierre.alusta@fda.hhs.gov (P.A.); dan.buzatu@fda.hhs.gov (D.A.B.)
* Correspondence: young.ahn@fda.hhs.gov; Tel.: +1-870-543-7084
† These authors contributed equally to this work.

Abstract: *Burkholderia cepacia* complex (BCC) contamination has resulted in recalls of non-sterile pharmaceutical products. The fast, sensitive, and specific detection of BCC is critical for ensuring the quality and safety of pharmaceutical products. In this study, a rapid flow cytometry-based detection method was developed using a fluorescence-labeled oligonucleotide *Kef* probe that specifically binds a *KefB/KefC* membrane protein sequence within BCC. Optimal conditions of a 1 nM *Kef* probe concentration at a 60 °C hybridization temperature for 30 min were determined and applied for the flow cytometry assay. The true-positive rate (sensitivity) and true-negative rate (specificity) of the *Kef* probe assay were 90% (18 positive out of 20 BCC species) and 88.9% (16 negative out of 18 non-BCC), respectively. The detection limit for *B. cenocepacia* AU1054 with the *Kef* probe flow cytometry assay in nuclease-free water was 1 CFU/mL. The average cell counts using the *Kef* probe assay from a concentration of 10 µg/mL chlorhexidine gluconate and 50 µg/mL benzalkonium chloride were similar to those of the RAPID-B total plate count (TPC). We demonstrate the potential of *Kef* probe flow cytometry as a more sensitive alternative to culture-based methods for detecting BCC in non-sterilized pharmaceutical raw materials and products with regards to water-based environments.

Keywords: *Burkholderia cepacia* complex; flow cytometry; fluorescence-labeled oligonucleotide probe

1. Introduction

The *Burkholderia cepacia* complex, otherwise known as BCC, is a group of bacteria comprising 24 different pathogenic species [1]. These species are Gram-negative, catalase-producing, and lactose-non-fermenting [2]. This group has been classified as objectionable microorganisms and opportunistic pathogens that are widespread in the environment, mainly in water and soil [1–4]. BCC relies on multiple survival mechanisms, including efflux pumps to extrude biocides or render them inactive for growth [2–5]. This can be observed in their ability to widely contaminate both non-sterile and sterile pharmaceuticals, causing potential life-threatening respiratory infections and serious health risks [6–8]. The threats of BCC transmission and spread mainly affect those with underlying and pre-existing health issues, such as individuals who are immunocompromised or have cystic fibrosis or acquired immunodeficiency syndrome [9]. Therefore, it is critical to determine total aerobic bacterial numbers in non-sterile pharmaceutical materials as part of the routine evaluation of microbiological quality [10,11]. Specifically, the detection of very low levels (100 colony-forming units (CFU)/mL) of contaminants is required to ensure acceptable pharmaceutical product quality and safety.
The United States Pharmacopeia (USP) has published a general chapter (USP <60>, Microbiological examination of non-sterile products: tests for Burkholderia cepacia complex) describing the tests needed to ensure that drug ingredients, pharmaceutical water, and finished drug products conform to appropriate quality standards [12]. These tests are mainly limited by their low sensitivity and have been shown to be relatively inaccurate with regards to the detection of BCC [4,13]. To overcome this sensitivity challenge, polymerase chain reaction (PCR), real-time quantitative PCR (qPCR), loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), and droplet digital PCR (ddPCR) have also been utilized to test for the presence of BCC [13–20]. PCR has been shown to be rapid, simple, easy to use, and relatively inexpensive for the detection of BCC [4]. LAMP and RPA are efficient isothermal methods that eliminate the need for a thermal cycler and have high deployment potential in resource-limited settings [4,18–20]. Two major limitations of qPCR are of particular concern, namely its inability to distinguish live from dead cells and the amplification reactions sensitivity to inhibitors.

One of the most commonly used methods to distinguish live and dead cells in bacterial samples is flow cytometry [21–25]. This method is highly sensitive, extremely precise, and is specifically noted for its ability to detect down to one single viable bacterial cell in a short period of time compared to other available methods. Most recently, flow cytometry has exhibited the highest sensitivity for detecting trace levels of BCC strains [14]. Although flow cytometry demonstrates advantages such as a short assay time and high sensitivity, specificity towards a target organism is necessary in non-sterile pharmaceutical products. Fluorophores can be coupled with flow cytometry to rapidly detect specific bacteria [25–27]. This is particularly useful in the case of BCC, as the ability to detect one single cell in a sample would be beneficial to effectively prevent and avoid potential contamination. Alexa Fluor 488 is known for its superior photostability and signal intensity and is stable at lower pH levels [28]. The higher fluorescence intensity of Alexa 488 conjugates is advantageous for applications in which a direct strong signal is needed to detect BCC. However, due to the probe’s length, it drastically reduces specificity towards BCC, thereby limiting its specific detection. While specifically developed for flow cytometry, its use has proven to be technically challenging.

Our aim is to establish a more efficient and cost-effective method to detect BCC in order to prevent widespread contamination. In this study, we developed a rapid-flow-cytometry-based detection method for BCC using an oligonucleotide probe targeting the inner-membrane protein of the KefB/KefC family sequence. After the optimization of the hybridization temperature and probe concentration, we tested the specificity and sensitivity of the developed assay. Finally, we applied the developed probe-based assay for the detection of BCC in antiseptics (i.e., 10 µg/mL chlorhexidine gluconate (CHX) or 50 µg/mL benzalkonium chloride (BZK)) and surface water.

2. Materials and Methods

2.1. Bacterial Strains and Preparation

The *Burkholderia* strains used in this study are listed in Table S1 in the Supplementary Materials. Thirty-six strains of *Burkholderia* spp. and two strains of *Caballeronia* spp. were obtained from the *Burkholderia cepacia* Research Laboratory and Repository at the University of Michigan. All 20 BCC strains and 18 non-BCC strains were cultivated as described previously [14].

To determine BCC in autoclaved nuclease-free water (Qiagen, Valencia, CA, USA) and antiseptics, samples were prepared in autoclaved nuclease-free water (23 January 2020), containing 10 µg/mL CHX (8 September 2020) and 50 µg/mL BZK (8 September 2020), then stored at 23 °C for 524, 295, and 295 consecutive days, as described previously [14,18].

2.2. Design of the Kef Probe

The inner-membrane protein of the KefB/KefC family (Kef) probe (5′-Alexa488-O-ATGCAGCGGCTCGTGTTCGG-3′) was designed as previously described [18]. The pep-
tide nucleic acid *Kef* probe was conjugated to Alexa Fluor 488 (Eurofins Genomics LLC, Louisville, KY, USA) and reconstituted prior to use in molecular-grade water to a 100 µM stock concentration.

### 2.3. RAPID-B Total Plate Count (TPC)

The TPC reagent used here contained thiazole orange (TO) and propidium iodide (PI), as described previously [23]. Thiazole orange is a cell-permeable dye which intercalates with the DNA of live cells, generating green fluorescence (FL1 channel). Only dead cells with compromised membranes may be penetrated by PI, which quenches the TO and emits red fluorescence (FL3 channel). As a result, combining these two dyes yields a quick approach for total cell quantification as well as distinguishing between live and dead cells (Supplementary Figure S1). BCC samples were prepared as previously described [14]. In summary, 1 mL of each dilution (10 and 10^2 CFU/mL) of BCC suspension was centrifuged at 16,300 × g for 5 min, and the cell pellets were washed twice with 1 mL of 1× phosphate-buffered saline (PBS; Sigma-Aldrich, St. Louis, MO, USA). The pellets (approx. 100 µL) were resuspended in 567 µL PBS, and 333 µL of TPC reagent was added to each suspension. The flow cytometer used was a model A40 flow cytometer (Apogee Flow Systems, Hemel Hempstead, UK).

### 2.4. Optimization of Kef Probe Assay for BCC

A Synergy MX spectrophotometer (BioTek Instruments, Winooski, VT, USA) was used to adjust the optimal density at 600 nm to around 0.1 (range = 0.095–0.105), which is equivalent to about 10^8 CFU/mL. Serial dilutions of each BCC suspension were prepared in 4 mL of autoclaved nuclease-free water to yield appropriate CFUs (10, 10^2, 10^3, and 10^4 CFU/mL), as previously described [14,18]. The *Kef* probe assay was performed by a modified method described previously in [25]. Briefly, the samples (10 and 10^2 CFU/mL) were centrifuged at 16,300 × g for 5 min, and the supernatant was removed. The cell pellets were washed with 1 mL of 1× PBS and centrifuged again at 16,300 × g for 5 min. The pellets were resuspended in 1 mL of 10% buffered formalin (Sigma-Aldrich, St. Louis, MO, USA) and incubated at room temperature for 30 min under gentle vortexing on a Vortex-Genie 2 (Daigger, Wheaton, IL, USA). The samples were centrifuged and washed with 1 mL 1× PBS. The pellets were resuspended in 290 µL hybridization buffer (20 mM Tris-HCl (pH 7.5), 5 mM EDTA, 3 M NaCl, and 0.01% SDS) and 10 µL of *Kef* probe and incubated at 60 °C for 30 min. After incubation of BCC, samples were washed with 1 mL hybridization buffer at 60 °C for 45 min with vortexing (1000 rpm). The samples were centrifuged again at 16,300 × g for 5 min. Pellets were resuspended in 1 mL 1× PBS and used for flow cytometric analyses.

Three different concentrations of the *Kef* probe, calculated to be 1, 10, and 100 nM, at temperatures of 55, 60, and 65 °C were tested to determine the optimal hybridization conditions. For control purposes, with or without cells, a blank *Kef* probe at 1, 10, and 100 nM with nuclease-free water was also analyzed. The samples were analyzed on the A40 flow cytometer to determine bacterial concentration [14]. This experiment was performed in triplicate.

### 2.5. True-Negative Rate (Specificity) in Kef Probe Assay

To investigate the specificity of the flow cytometer with the newly designed *Kef* probe, 20 BCC strains and 18 non-BCC strains were analyzed, three times each, using the TPC assay and *Kef* probe assay as described above, and the averages were calculated. Based on the *Kef* probe blank counts, positive results were recorded (0 = not detected, 1 = detected) that confirmed counts above 10^3 cells/mL (i.e., 100 events/100 µL). The formula used to calculate the estimated specificity is as follows: estimated specificity (%) = number of true-negative events (TN)/(number of false-positive events (FP) + TN) × 100 [29].
2.6. Limit of Detection (LOD) in Kef Probe Assay

The LOD was measured using the Kef probe assay and by analyzing tenfold serial dilutions (10^3, 10^2, 10, and 1 CFU/mL) of *B. cenocepacia* AU1054. A Kef probe assay was considered positive when the counts were above 10^3 cells/mL.

2.7. Comparison of TPC and Kef Probe Assay

2.7.1. BCC-Spiked 10 µg/mL CHX and 50 µg/mL BZK Samples

Prior to the Kef probe assay, the total bacterial population was measured using a TPC assay. For control purposes, a blank Kef probe with nuclease-free water and 10 µg/mL CHX and 50 µg/mL BZK blank samples (non-BCC-spiked) were analyzed on the flow cytometer. BCC-spiked 10 µg/mL CHX and 50 µg/mL BZK samples were prepared (8 September 2020) and stored at 23 °C for 295 consecutive days, as previously described [18]. To compare the Kef probe assay with the TPC assay, *B. cenocepacia* AU0222, *B. cepacia* PC783, *B. cepacia* AU24442, and *B. stabilis* AU23340 suspensions were prepared as described above using a dilution equivalent to 10 CFU/mL.

2.7.2. Surface Water

Using sterilized 50 mL conical tubes (Eppendorf, Enfield, CT, USA), six water samples were collected in July 2021 from surface waters in Arkansas including: Arkansas River in Jefferson, AR (07/22/21); Creek 1 in Bryant, AR (07/25/21); Creek 2 in Little Rock, AR (07/25/21); Creek 3 in Hot Springs Village, AR (07/25/21); and tap water and cold fountain water in Hot Springs, AR (07/26/21) as drinking water.

In order to obtain total bacteria counts, 10 µL aliquots of serial dilutions of each water sample were dropped directly onto 1/10 strength tryptic soy agar (1/10 × TSA) and 1/10 × TSA with *Burkholderia cepacia* selective supplement (200 µL of *Burkholderia cepacia* selective supplement containing polymyxin B (150,000 IU/L; 3.75 µg/mL), gentamicin (5 µg/mL), and ticarcillin (100 µg/mL): Oxoid, Lenexa, KS, USA) [30]. The plates were incubated at room temperature (23 °C) for 48 h before enumeration.

For the flow cytometric determination of BCC from surface water, we counted directly from surface water and from water samples spiked with *B. cenocepacia* HI2976. Prior to the Kef probe assay, the total bacterial population was measured using the TPC assay from non-spiked and BCC-spiked samples. For non-spiked water samples, dilutions were prepared to approximate 10 CFU/mL based on the above results. For BCC-spiked samples, 900 µL of the water sample was spiked with 100 µL of *B. cenocepacia* HI2976 (the BCC cell concentration was approximately 1.5 × 10^8 cells/mL) and exposed to water for 1 h to allow *B. cenocepacia* HI2976 cells to equilibrate with the ambient environmental conditions. The dilutions were prepared to approximately 10 CFU/mL based on non-spiked water samples. The BCC-spiked and non-spiked samples were analyzed using the TPC and Kef probe assays, as described above. For negative control purposes, a filtered (0.2 µm pore size, 25 mm in diameter) blank sample was also analyzed.

3. Results

3.1. Kef Probe Designed for Flow Cytometry

Using the genome-gene matrix (GGM), we identified 197 BCC-specific fragments (20–40 bp) that are only present in BCC genomes. Among the 197 BCC-specific fragments, we chose fragment 4056 (20 bp) (the inner membrane protein of the KefB/KefC family), which showed 100% sequence identity, and three copies (orthologues) in BCC. This allowed for more binding areas on the cell surface, and thus more fluorescence, which facilitated the identification of BCC in the flow cytometer when counting cells. The Kef probes had a 65% G+C content, a melting temperature of 66.6 °C, and a length of 20 bases.

3.2. Optimal Concentration and Temperature of Hybridization Kef Probe

Three different concentrations of the Kef probe (1, 10, and 100 nM) were tested to find the optimal concentration that would enable the efficient detection of BCC (Figure 1).
The three different concentrations of the Kef probe at 1, 10, and 100 nM corresponded to 2164.2, 2589.2, and 2151.7 cells/mL for every 10 CFU/mL of *B. cenocepacia* AU1054, respectively (Figure 1a). However, the main difference was observed with blanks at concentrations of 1 and 10 nM, which had the lowest number of cells/mL (280.8 and 670.8). A concentration of 100 nM showed a high background fluorescence with 1432.5 cells/mL, which could potentially yield false-positive results. Based on observations of the blanks, values above $10^3$ cells/mL (i.e., $10^2$ events/100 µL) were considered positive. A minimum of $10^2$ events/100 µL for each sample were counted, suggesting that the 1 nM concentration was optimal, as a high number of events on a blank would be undesirable.

To find the optimal temperature for the Kef probes, three temperatures (55, 60, and 65 °C) were tested and compared with the TPC results (Figure 1b). The optimal temperature for the Kef probe hybridization is the temperature that allows for the counts to be closest to those of the TPC assay. The TPC assay yielded counts of 660–1110 cells/mL. The Kef probe assay counts were obviously different below 55 °C (1340–1660 cells/mL, i.e., more than $10^2$ events/100 µL) and above 65 °C (110–540 cells/mL) ($p < 0.05$). The Kef probe assay at 60 °C (820–1120 cells/mL), being the closest to the TPC, was selected to be the optimal temperature for the use of the Kef probe.

### 3.3. True-Positive Rate (Sensitivity) and True-Negative Rate (Specificity)

To investigate the specificity of flow cytometry with the newly designed Kef probe, 20 BCC strains and 18 non-BCC strains were subjected to the probe assay. The 38 *Burkholderia* strains were individually serially diluted, and about $10^2$ CFU/mL was used for the hybridization reaction. As shown in Figure 2a, the 20 BCC strain numbers determined by the TPC assay averaged 2999.3 cells/mL, and an average of 1842.9 cells/mL when the cell number estimates were based on the Kef probe. The Kef probe counted over $10^3$ cells/mL for 18 BCC strains. The average cell numbers of *B. contaminans* HI3429 (793.3 cells/mL; ranging from 810 to 1190 cells/mL) and *B. diffusa* AU1075 (902.2 cells/mL; ranging from 790 to 1660 cells/mL) were below $10^3$ cells/mL. Positive results were recorded (0 = not detected, 1 = detected) that confirmed counts above $10^3$ cells/mL. The sensitivity of the Kef probe was 90% ((number of true-positive events (TP))/(TP + number of false-negative events (FN))) × $100 = 18/(18 + 2) × 100 = 90\%$ sensitivity; 18 positives out of 20) (Figure 2b).
Figure 2. Comparison of specificity of Kef probe for 100 CFU/mL of 20 BCC strains (a,b) and 18 non-BCC strains (c,d) using flow cytometry. * Indicates statistically significant differences from TPC (p < 0.001). Statistical analysis was performed via a paired t-test using SigmaPlot vs. 13.0 software. See Figure 1 for legends.

The cell concentrations of 18 non-BCC strains were determined by TPC, averaging 1934.5 cells/mL, whereas an average of 349.9 cells/mL was obtained by the Kef probe assay (Figure 2c). The Kef probe counted less than 10^3 cells/mL for 16 non-BCC strains. The counts for B. fungorum AU35949 (1063.3 cells/mL) and Caballeronia zhejiangensis AU12096 (1035.6 cells/mL) were above 10^3 cells/mL. Based on these results, the specificity of the Kef probe was 88.9% ((number of true-negative events (TN)/(number of false-positive events (FP) + TN) × 100 = 16/(2 + 16) × 100 = 88.9%; 16 negatives out of 18) (Figure 2d).

3.4. Limit of Detection (LOD) of the Flow Cytometry Assay

To determine the LOD of the flow cytometry assay, we tested the Kef probe using diluted solutions of B. cepacia AU1054 (Figure 3). The counts for B. cepacia AU1054 (1, 10, 10^2, and 10^3 CFU/mL) were determined by TPC, averaging 2003.3 cells/mL, 2082.2 cells/mL, 3627.8 cells/mL, and 22397.8 cells/mL, respectively. When cell number estimates were solely based on the Kef probe assay, the abundances (average: n = 9) of B. cepacia AU1054 (1, 10, 10^2, and 10^3 CFU/mL) averaged 1438.9, 2244.4, 3358.9, and 4041.1 cells/mL, respectively. Analysis by probe clearly detected 1 CFU/mL, which is equivalent to 1438.9 cells/mL (143.8 events/100 µL) in a test reaction and appeared to be strongly associated with CFU/mL ($r^2 = 0.7484; y = 1.6552x + 173.5$) (Figure 3).
Figure 3. Limit of detection (LOD) of flow cytometry using 10-fold serial dilutions of *B. cenocepacia* AU1054 ranging from 1 to 10$^3$ CFU/mL.

3.5. Counting BCC from Antiseptic Solutions and Surface Water with the Kef Probe Assay

3.5.1. Long-Term Storage in 10 µg/mL CHX and 50 µg/mL BZK

A comparison of the sensitivity of the TPC and *Kef* probe assay used to detect BCC strains from 10 µg/mL CHX and 50 µg/mL BZK kept at 25 °C for 295 days is presented in Figure 4. The average *Kef* probe assay at a concentration of 10 µg/mL CHX averaged 1665.0 cells/mL, for 10 CFU/mL (Figure 4a). Similarly, the average cell count using the TPC assay averaged 1694.9 cells/mL. However, the TPC assay for *B. stabilis* AU23340 averaged 697.8 cells/mL, whereas the *Kef* probe cell count averaged 2588.3 cells/mL (Figure 4b).

At a concentration of 50 µg/mL BZK, the TPC and *Kef* probe assay were similar, yielding counts of 1993.9 cells/mL and 1761.0 cells/mL, respectively (Figure 4c). However, the count for *B. stabilis* AU23340 quantified by TPC averaged 3966.7 cells/mL, whereas an average of 966.7 cells/mL was obtained by the *Kef* probe assay (Figure 4d).

(a) ![Graph](image1)

(b) ![Graph](image2)

Figure 4. Cont.
Figure 4. Bacterial abundance assessed for 10 CFU/mL by the TPC and Kef probe assays using flow cytometry in CHX (a,b) and BZK (c,d). There were no significant differences between probe and TPC (a: \( p = 0.329 \), c: \( p = 0.981 \)). Statistical analysis was performed via a paired t-test using SigmaPlot vs. 13.0 software.

3.5.2. Surface Water

Six surface water samples (four non-drinking water and two drinking water samples) were collected and analyzed to determine whether the Kef probe can distinguish BCC from other microbial populations commonly present in water sources. We counted a total of \( 10^3 \)–\( 10^5 \) CFU/mL on 1/10\( \times \) TSA inoculated with each of the six surface water samples (data not shown). The plate cultures could not enumerate BCC on 1/10\( \times \) TSA with \textit{Burkholderia cepacia} selective supplement. Consequently, we spiked the water samples with BCC prior to flow cytometry analyses.

BCC-spiked water samples were individually serially diluted, and about 10 CFU/mL was used for flow cytometry. The average results for the TPC cell counts ranged from 1892.2 to 6271.1 cells/mL for the six different samples (Figure 5). The Kef probe cell counts for the water samples (non-spiked with BCC) did not show any BCC (data not shown), but the Kef probe cell counts for the BCC-spiked samples yielded average counts ranging from 110 to 1546 cells/mL. As shown in Figure 5, samples collected from the Arkansas River and drinking water (tap water and fountain water) had average counts ranging between 1057.1 and 1546.6 cells/mL. Less than \( 10^3 \) cells/mL BCC were detected in Creek 1 (778.9 cells/mL), Creek 2 (110), and Creek 3 (196.7 cells/mL) using the Kef probe assay in samples spiked with BCC.

Figure 5. Bacterial abundance assessed in several different surface water samples; spiked with \textit{B. cenocepacia} HI2976 (10 CFU/mL) using the TPC and Kef probe assays.
4. Discussion

The BCC contamination of unsterilized pharmaceutical products is a major concern and has been responsible for multiple recalls in the past few years. The *Kef*-probe-based flow cytometric assay for the specific detection of BCC—as described here—can detect 1 CFU/mL at a concentration of 1 nM *Kef* probe at 60 °C. We demonstrated that the *Kef* probe assay, using flow cytometry, was able to detect BCC in antiseptics after 295 days and in drinking water after the optimization of the *Kef* probe.

The flow-cytometry-based system, RAPID-B, is a well-established method for counting and assessing the viability of bacteria in real time [14,21–24]. To analyze mixed microbiota, RAPID-B genetic-based assays have been developed, resulting in an assay that can be run at a much lower cost and over a shorter timeframe, with a high sensitivity and specificity [25]. Using a 5′-Alexa Fluor 488 dye-conjugated oligonucleotide probe, we can detect a small number of *Escherichia coli* cells in the presence of large numbers of other bacteria, because a single *E. coli* cell harbors many copies of 5S, 16S-like, and 23S-like rRNAs in 10^5 ribosomes [26]. The more orthologues there are, the more target regions for the hybridization of the probes when using flow cytometry. Indeed, individual cells can be identified by radiolabeled oligonucleotides due to the high number of copies [31]. In this study, increased fluorescence allowed BCC to be identified due to three orthologue copies and their makeup having 100% sequence identity, which the probe was designed for. Our experiments demonstrated that the *Kef* probe was optimal for detecting BCC in conjunction with flow cytometry. Here, 90% sensitivity (i.e., the number of true-positive events) was demonstrated using flow cytometry. Among the 20 BCC strains, the cell numbers of *B. contaminans* HI3429 and *B. diffusa* AU1075 ranged from 790 to 1660 cells/mL, which is considered positive. Since a cell count of 280.8 cells/mL was observed with blanks at concentrations of 1 nM, we used a cutoff value of over 500 cells/mL instead of 10^3. In addition, if at least one out of five replicates had a count over 10^3 cells/mL, the event was labeled “TP”. Even though these counts were close to 10^3 cells/mL, the failure to detect these strains may have been due to a lack of cell permeabilization during the hybridization process, or more likely the low efficiency of the probe binding to the target [26]. Another possible explanation is that the physiological status of cells is directly correlated to signal intensity, which is not measured [32]. Conversely, among the 20 non-BCC strains, *B. contaminans* HI3429 and *Caballeronia zhejiangensis* AU12096 resulted in cell count averages above 10^3 cell/mL, which is indicative of false-positive events. These results may be explained by the presence of an unspecified binding site within these two strains [27]. No such sequences were found by BLAST analysis in the two non-BCC strains that tested positive with the *Kef* probe. The relatively high sensitivity and specificity of the *Kef* probe makes it an appropriate choice for the flow cytometric identification and enumeration of BCC.

In the present study, different concentrations of the probe and varying temperatures were tested to determine the optimal conditions for the assay. Xue et al. [25] used a 220 nM DNA probe (from a stock solution of 200 ng/µL) and an incubation temperature of 55 °C for 30 min. Joachimsthal and co-workers added a fluorescently labeled probe at a rate of 100 pmol/mL (100 nM) at 40 or 46 °C for 30 min [27]. In preparation for flow cytometry analysis, the final cell concentrations were approximately 10^6–10^9 cells/mL. The highest sensitivity for detecting over 10^6 cells/mL requires higher probe concentrations [25,27]. In order to keep the background fluorescence low, it is beneficial to use the minimum concentration of the *Kef* probe required to detect BCC cells ranging from 1 to 10^3 CFU/mL. We tested three concentrations (1, 10, and 100 nM), which yielded comparable event counts per milliliter at a concentration of 10 CFU/mL. The use of the *Kef* probe at a concentration of 1 nM is considered optimal, since it is sufficient to hybridize 10^3 CFU/mL of BCC strains. Furthermore, for control purposes, *Kef* probe blanks with only CHX and BZK added were also analyzed on the flow cytometer; they showed 265 and 216 events/100 µL, respectively, which are considered positive results. These background fluorescence results were similar to our previously obtained TPC assay results [14]. In order to reduce false positive results for the *Kef* probe assay, CHX and BZK (negative control) samples were washed...
in 1× PBS, similar to the treated or spiked samples. False-positive counts (at approximately 300 events/100 µL) were discarded by adjusting the cutoff value. Consequently, the lowest probe concentration yielded low background fluorescence, sufficient to hybridize 10^3 CFU/mL of BCC strains.

BCC in nuclease-free water, as well as BCC in CHX and BZK solutions, was previously detected down to 1 CFU/mL by the flow cytometric method using a TPC assay [14]. This LOD is ideal and provides a decent detection strategy for pharmaceutical products where BCC contamination is possible. Low event counts in pharmaceutical products often evade detection; consequently, a trace-level detection technology is essential. The current study confirms that the Kef probe assay can detect BCC specifically down to 1 CFU/mL. The assay’s useful range is from 1 to 10^3 CFU/mL. The results show that the reaction saturation for the Kef probe was reached at a concentration of 10^4 CFU/mL. Therefore, it was impossible to quantify the number of counts at this concentration. For instance, with 10^4 CFU/mL B. cenocepacia AU1054, the TPC averaged 22,397.8 ± 3308.8 cells/mL, while the Kef probe cell counts averaged 4041.1 ± 345.3 cells/mL. The cell number according to the TPC assay should have been similar to the Kef probe assay, but they showed a ten-fold difference (Figure 3). Concurrently, with B. cenocepacia AU1054 cell concentrations below 10^3 CFU/mL, the cell counts observed by the TPC and Kef probe assays remain comparable. These results indicate that at higher cell densities, our 1 nM Kef probe concentration may be limited to accurately quantifying higher BCC cell numbers. However, based on the fact that the detection of BCC in pharmaceutical products requires a trace-level detection capability, the working range of the Kef probe assay from 10^0 to 10^3 CFU/mL is very applicable. It is also undesirable to increase the probe concentration in order to pick up higher cell concentrations of BCC, since the fluorescence background would increase, which could produce false-positive results. To overcome this problem, ensuring the use of under 10^3 CFU/mL with the Kef probe at a concentration of 1 nM will allow for accurate BCC detection.

Flow cytometry is a very sensitive method allowing for high-precision detection, at the level of one viable bacterial cell, in a short period of time [14,21–25]. Furthermore, previous work by our co-authors has shown that the TPC assay containing DNA dyes can stain bacterial cells to assess whether they are alive, injured, or dead [21]; this was applied to assess the effectiveness of different antiseptics on BCC [14]. However, these tests may be limited by their specificity [25–27]. The TPC assay is a generic live/dead assay for all bacteria and lacks specificity. Previous studies also demonstrated that the flow cytometry genetic probe assays can be pathogen-specific and detect trace levels of the pathogen [25,27]. In this study, we demonstrated the similar sensitivity (true-positive rate) of the TPC and Kef probe assays for detecting BCC at 10 CFU/mL in CHX and BZK solutions. The only exception was B. stabilis AU23340 (Figure 4). In CHX, with B. stabilis AU23340, the Kef probe assay yielded a much higher event count compared to the TPC assay. A possible explanation for this result could be the incomplete washing out of the non-specifically bound Kef probe. As shown in our previous work, multiple washing reduced background fluorescence [14]. Conversely, the Kef probe assay in BZK solution with B. stabilis AU23340 yielded a much lower event count compared to the TPC assay. This may be explained by the less-than-optimum hybridization conditions for the Kef probe to bind B. stabilis, as theoretically we should have seen binding similar to that with BCC. Overall, although the CHX and BZK (negative control) samples needed to be washed in PBS to reduce the presence of random particulate matter, similar results for the Kef probe and TPC assays were obtained in both CHX and BZK samples.

Tests on surface water were also performed in order to determine whether the Kef probe assay can distinguish BCC from other naturally occurring bacteria, since multiple microbial populations are commonly present in pharmaceutical-grade water. Furthermore, non-drinking surface water comprises high concentrations of interfering particles such as bacteria and organic as well as inorganic particles [33,34]. Our surface water samples did yield different results depending on the amount of organic and inorganic particles present.
BCC-spiked drinking water (tap water and cold fountain water) showed average counts reaching over $10^3$ cells/mL of bacteria for the TPC and Kef probe assays, which is a positive result. However, Creeks 2 and 3 presented a relatively low amount of detected BCC (less than $10^3$ cells/mL) compared to other samples (Figure 5). Indeed, this may be due to the presence of many interfering particles in Creeks 2 (2967.0 ± 140.1) and 3 (2970.0 ± 132.3) compared to the other filtered blank samples. This shows that the presence of higher concentrations of particulate matter can negatively affect enumeration. Conversely, the lower amounts of particles in water samples such as in drinking water will increase the accuracy of BCC detection.

While using flow cytometry to analyze water samples remains challenging, a few general concerns are worth mentioning. First, BCC-specific probe design is one of the main limiting factors, due to the close genomic and phenomic relatedness between BCC and other *Burkholderia* strains. Readily available complete genome sequence data of *Burkholderia* will ensure more specific probe design (i.e., further sequence surveys will lead to improved probe design). Despite the fact that our probe design covers all BCC strains, we were unable to test two major strains encountered in cystic fibrosis patients, namely *B. multivorans*, and *B. vietnamiensis*, due to a stock shortage. Furthermore, the relatively small size of the oligonucleotide hybridization probes minimizes the problems of cellular permeability and access to binding sites. Secondly, even though flow cytometry is a highly sensitive method, the enumeration of rare events (i.e., 1 targeted cell overshadowed by 1,000,000 non-targeted cells) is extremely difficult [35]. The Kef probe assay, intended for BCC detection in environmental water samples, should be adjusted in terms of the cell number with regard to the sample matrix. The pre-enrichment of water samples in 1/10× TSB prior to flow cytometry analyses seems useful in recovering BCC cells that may be in a debilitated state [30,36,37]. Thirdly, using flow cytometry to analyze dirty water samples remains challenging and requires the mechanical or optical separation of cells from interfering particles [33,34]. For this problem, it has been previously demonstrated that centrifugation using a gradient medium such as Percoll® allows the cleanup of dirty matrices [22]. It is possible that this method could be used in future studies to significantly reduce background fluorescence due to particulate matter. Fourthly, the more wash steps the samples undergo, the less accurate and absolute the event counts will be. Consequently, to minimize error margins, it is recommended for samples to be examined repeatedly. Specifically, antiseptics such as CHX and BZK (negative control) samples need to be washed, since they exhibit autofluorescence. In the event of high background fluorescence emanating from the matrix, samples may be subject to photobleaching. Lastly, 10% buffered formalin kills surviving bacteria, suggesting that the Kef probe assay is unable to discern dead from live cells, as seen with the TPC assay. Further studies are required to evaluate alternative approaches.

5. Conclusions

BCC continues to be a major issue in pharmaceutical product contamination, and therefore better detection methods than those currently available are in high demand. This study showed that the combination of a fluorescent-labeled Kef probe, designed from a housekeeping gene, with flow cytometry is a powerful tool to provide specific, sensitive, and accurate BCC detection in water-based environments. The Kef probe-based flow cytometry assay described here demonstrated its effectiveness with its ability to detect 1 CFU/mL of BCC. The ability to detect BCC in various solutions, including the two antiseptics CHX and BZK, has implications for the assay’s potential. Furthermore, the assay was optimized to be simple and cost-effective to ensure reproducibility. Due to growing concerns for possible BCC contamination and other rising health issues, a detection assay such as that used in this study has the potential to improve public health.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms10061170/s1, Table S1. True-positive rate (sensitivity) and true-negative rate (specificity) of flow cytometric assay for BCC; Table S2. BCC cluster
analysis of conserved regions in the multiple sequence alignment (MSA); Figure S1. Flow cytometric analysis of BCC through serial gates by the Kef probe (A) and TPC assays (B).

**Author Contributions:** Conceptualization, S.D.G., A.W., D.L., O.K., P.A., D.A.B. and Y.A.; methodology, S.D.G., A.W. and Y.A.; data analysis, S.D.G., A.W., D.L. and Y.A.; writing—original draft preparation, S.D.G., A.W., D.L. and Y.A.; writing—review and editing, S.D.G., A.W., O.K., P.A., D.A.B. and Y.A.; supervision, project administration, and funding acquisition, D.A.B. and Y.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the United States Food and Drug Administration.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** We thank Carl E. Cerniglia for the help and support. We also thank Ashraf Khan and Jinshan Jin for the critical review of the manuscript. This research was supported in part by the summer student research program (D. Le) and an appointment of the Research Participation Program (S. Daddy Gaoh) at the National Center for Toxicological Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Food and Drug Administration. The views expressed herein do not necessarily reflect those of the U.S. Food and Drug Administration or the U.S. Department of Health and Human Services.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The findings and conclusions presented in this manuscript are those of the authors and do not necessarily represent the views of the U.S. Food and Drug Administration.

**References**

1. Depoorter, E.; De Canck, E.; Peeters, C.; Wieme, A.D.; Cnockaert, M.; Zlosnik, J.E.A.; LiPuma, J.J.; Coenye, T.; Vandamme, P. *Burkholderia cepacia* complex Taxon K: Where to split? *Front. Microbiol.* 2020, 11, 1594. [CrossRef]

2. Mahenthiralingam, E.; Urban, T.A.; Goldberg, J.B. The multifarious, multireplicon *Burkholderia cepacia* complex. *Nat. Rev. Microbiol.* 2005, 3, 144–156. [CrossRef]

3. Tavares, M.; Kozak, M.; Balola, A.; Coutinho, C.P.; Godinho, C.P.; Hassan, A.A.; Cooper, V.S.; Sa-Correia, I. Adaptation and survival of *Burkholderia cepacia* and *B. contaminans* during long-term incubation in saline solutions containing benzalkonium chloride. *Front. Bioeng. Biotechnol.* 2020, 8, 630. [CrossRef] [PubMed]

4. Tavares, M.; Kozak, M.; Balola, A.; Sa-Correia, I. *Burkholderia cepacia* complex bacteria: A feared contamination risk in water-based pharmaceutical products. *Clin. Microbiol. Rev.* 2020, 33, e00139-19. [CrossRef]

5. Ahn, Y.; Kim, J.M.; Kweon, O.; Kim, S.J.; Jones, R.C.; Woodling, K.; Gamboa da Costa, G.; LiPuma, J.J.; Hussong, D.; Marasa, B.S.; et al. Intrinsic resistance of *Burkholderia cepacia* complex to benzalkonium chloride. *MBio* 2016, 7, e01716-16. [CrossRef] [PubMed]

6. Dos Santos Saalfeld, S.M.; Shinohara, D.R.; Dos Anjos Szczerepa, M.M.; Martinez, H.V.; Vieira de Campos, E.; Mitsugui, C.S.; Oliveira, A.R.; Granzotto, D.C.T.; Nishiyama, S.A.B.; Tognim, M.C.B. Consecutive outbreaks of *Burkholderia cepacia* complex caused by intrinsically contaminated chlorhexidine mouthwashes. *Am. J. Infect. Control* 2020, 48, 1348–1353. [CrossRef]

7. Sutton, S.; Jimenez, L. A review of reported recalls involving microbiological control 2004–2011 with emphasis on FDA consideration of “objectionable organisms”. *Am. Pharm. Rev.* 2012, 15, 42–57.

8. Jimenez, L. Microbial diversity in pharmaceutical product recalls and environments. *PDA J. Pharm. Sci. Technol.* 2007, 61, 383–399.

9. David, J.; Bell, R.E.; Clark, G.C. Mechanisms of disease: Host-pathogen interactions between *Burkholderia* species and lung epithelial cells. *Front. Cell. Infect. Microbiol.* 2015, 5, 80. [CrossRef] [PubMed]

10. USP. <61> Microbiological Examination of Nonsterile Products—Microbial Enumeration Tests. 2016. Available online: https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/q05b_pf_ira_34_6_2008.pdf (accessed on 1 March 2022).

11. USP. <1111> Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use. 2016. Available online: https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/q05c_pf_ira_33_2_2007.pdf (accessed on 1 March 2022).

12. USP. <60> Microbiological Examination of Nonsterile Products—Tests for *Burkholderia cepacia* Complex. 2018. Available online: http://www.usppf.com/pf/pub/data/v445/CHA_IPR_445_c60.xml (accessed on 1 March 2022).
13. Attia, M.A.; Ali, A.E.; Essam, T.M.; Amin, M.A. Direct detection of Burkholderia cepacia in susceptible pharmaceutical products using semi-nested PCR. *PDA J. Pharm. Sci. Technol.* 2016, 70, 99–108. [CrossRef]

14. Ahn, Y.; Gibson, B.; Williams, A.; Alusta, P.; Buzatu, D.A.; Lee, Y.J.; LiPuma, J.J.; Hussong, D.; Marasa, B.; Cerniglia, C.E. A comparison of culture-based, real-time PCR, droplet digital PCR and flow cytometric methods for the detection of Burkholderia cepacia complex in nuclelease-free water and antiseptics. *J. Ind. Microbiol. Biotechnol.* 2020, 47, 475–484. [CrossRef] [PubMed]

15. Mahenthiralingam, E.; Bischof, J.; Byrne, S.K.; Radomski, C.; Davies, J.E.; Av-Gay, Y.; Vandamme, P. DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, *Burkholderia vietnamiensis*, *Burkholderia multivorans*, *Burkholderia stabilis*, and *Burkholderia cepacia* genomovars I and III. *J. Clin. Microbiol.* 2000, 38, 3165–3173. [CrossRef]

16. Jimenez, L.; Hashiari, T.; Vasquez, J.; Zapata, S.; Bochis, J.; Kulko, M.; Ellman, V.; Gardner, M.; Choe, T. Real-time PCR detection of *Burkholderia cepacia* complex in pharmaceutical products contaminated with low levels of bacterial contamination. *PDA J. Pharm. Sci. Technol.* 2018, 72, 73–80. [CrossRef]

17. Furlan, J.P.; Pitmon-Silva, A.; Braz, V.S.; Gallo, I.F.L.; Stirling, E.G. Evaluation of different molecular and phenotypic methods for identification of environmental *Burkholderia cepacia* complex. *World J. Microbiol. Biotechnol.* 2019, 35, 39. [CrossRef]

18. Daddy Gaoh, S.; Kweon, O.; Lee, Y.-J.; LiPuma, J.J.; Hussong, D.; Marasa, B.; Ahn, Y. Loop-mediated isothermal amplification (LAMP) assay for detecting *Burkholderia cepacia* complex in non-sterile pharmaceutical products. *Pathogens* 2021, 10, 1071. [CrossRef] [PubMed]

19. Li, J.; Zhong, Q.; Shang, M.Y.; Li, M.; Jiang, Y.S.; Zou, J.J.; Ma, S.S.; Huang, Q.; Lu, W.P. Preliminary evaluation of rapid visual identification of *Burkholderia pseudomallei* using a newly developed lateral flow strip-based recombinase polymerase amplification (LF-RPA) system. *Front. Cell. Infect. Microbiol.* 2021, 11, 804737. [CrossRef] [PubMed]

20. Peng, Y.; Zheng, X.; Kan, B.; Li, W.; Zhang, W.; Jiang, T.; Lu, J.; Qin, A. Rapid detection of *Burkholderia pseudomallei* with a lateral flow recombinase polymerase amplification assay. *PLoS ONE* 2019, 14, e0213416. [CrossRef] [PubMed]

21. Buzatu, D.A.; Cooper, W.M.; Summage-West, C.; Sutherland, J.B.; Williams, A.J.; Bass, D.A.; Smith, L.L.; Woodruff, R.S.; Christian, J.M.; Reid, S.; et al. Photobleaching with phloxine B sensitizer to reduce food matrix interference for detection of *Escherichia coli* serotype O157:H7 in fresh spinach by flow cytometry. *Food Microbiol.* 2013, 36, 416–425. [CrossRef]

22. Wilkes, J.G.; Tucker, R.K.; Montgomery, J.A.; Cooper, W.M.; Sutherland, J.B.; Buzatu, D.A. Reduction of food matrix interference by a combination of sample preparation and multi-dimensional gating techniques to facilitate rapid, high sensitivity analysis for *Escherichia coli* serotype O157 by flow cytometry. *Food Microbiol.* 2012, 30, 281–288. [CrossRef] [PubMed]

23. Williams, A.J.; Cooper, W.M.; Ramsaroop, S.; Alusta, P.; Buzatu, D.A.; Wilkes, J.G. Rapid flow cytometry detection of a single viable *Escherichia coli* O157:H7 cell in raw spinach using a simplified sample preparation technique. *Front. Microbiol.* 2017, 8, 1493. [CrossRef]

24. Williams, A.J.; Cooper, W.M.; Summage-West, C.V.; Sims, L.M.; Woodruff, R.; Christman, J.; Moskal, T.J.; Ramsaroop, S.; Sutherland, J.B.; Alusta, P.; et al. Level 2 validation of a flow cytometric method for detection of *Escherichia coli* O157:H7 in raw spinach. *Int. J. Food Microbiol.* 2015, 215, 1–6. [CrossRef] [PubMed]

25. Xue, Y.; Wilkes, J.G.; Moskal, T.J.; Williams, A.J.; Cooper, W.M.; Nayak, R.; Rafii, F.; Buzatu, D.A. Development of a flow cytometry-based method for rapid detection of *Escherichia coli* serotype O157:H7 and *Shigella* spp. using an oligonucleotide probe. *PLoS ONE* 2016, 11, e0150038. [CrossRef]

26. Amann, R.I.; Binder, B.J.; Olson, R.J.; Chisholm, S.W.; Devereux, R.; Stahl, D.A. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. *Appl. Environ. Microbiol.* 1990, 56, 1919–1925. [CrossRef]

27. Joachimsthal, E.L.; Ivanov, V.; Tay, S.T.L.; Tay, J.H. Quantification of whole-cell in situ hybridization with oligonucleotide probes by flow cytometry of *Escherichia coli* cells. *World J. Microbiol. Biotechnol.* 2003, 19, 527–533. [CrossRef]

28. Panchuk-Voloshina, N.; Haugland, R.P.; Bishop-Stewart, J.; Bhalgat, M.K.; Millard, P.J.; Mao, F.; Leung, W.Y.; Haugland, R.P. Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. *J. Histochem. Cytochem.* 1999, 47, 1179–1188. [CrossRef]

29. FDA. Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests—Guidance for Industry and FDA Staff. 2007. Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda (accessed on 1 March 2022).

30. Ahn, Y.; Kim, J.M.; Ahn, H.; Lee, Y.J.; LiPuma, J.J.; Hussong, D.; Cerniglia, C.E. Evaluation of liquid and solid culture media for the recovery and enrichment of Burkholderia cenocepacia from distilled water. *J. Ind. Microbiol. Biotechnol.* 2014, 41, 1109–1118. [CrossRef] [PubMed]

31. Giovannoni, S.J.; DeLong, E.F.; Olsen, G.J.; Pace, N.R. Phylogenetic group-specific oligodeoxynucleotide probes for identification of single microbial cells. *J. Bacteriol.* 1988, 170, 720–726. [CrossRef] [PubMed]

32. DeLong, E.F.; Wickham, G.S.; Pace, N.R. Phylogenetic stains: Ribosomal RNA-based probes for the identification of single cells. *Science* 1989, 243, 1360–1363. [CrossRef] [PubMed]

33. Czechowska, K.; Johnson, D.R.; van der Meer, J.R. Use of flow cytometric methods for single-cell analysis in environmental microbiology. *Curr. Opin. Microbiol.* 2008, 11, 205–212. [CrossRef] [PubMed]

34. Frossard, A.; Hammers, F.; Gessner, M.O. Flow cytometric assessment of bacterial abundance in soils, sediments and sludge. *Front. Microbiol.* 2016, 7, 903. [CrossRef] [PubMed]

35. Joux, F.; Lebaron, P. Use of fluorescent probes to assess physiological functions of bacteria at single-cell level. *Microbes Infect.* 2000, 2, 1523–1535. [CrossRef] [PubMed]
36. Ahn, Y.; Lee, U.J.; Lee, Y.J.; LiPuma, J.J.; Hussong, D.; Marasa, B.; Cerniglia, C.E. Oligotrophic media compared with a tryptic soy agar or broth for the recovery of *Burkholderia cepacia* complex from different storage temperatures and culture conditions. *J. Microbiol. Biotechnol.* **2019**, *29*, 1495–1505. [CrossRef] [PubMed]

37. Kim, J.M.; Ahn, Y.; LiPuma, J.J.; Hussong, D.; Cerniglia, C.E. Survival and susceptibility of *Burkholderia cepacia* complex in chlorhexidine gluconate and benzalkonium chloride. *J. Ind. Microbiol. Biotechnol.* **2015**, *42*, 905–913. [CrossRef] [PubMed]